sbt6050 + cemiplimab

SBT6050 + cemiplimab is an investigational **combination therapy** under clinical evaluation for the treatment of HER2-expressing solid tumors, such as non-small cell lung cancer and gastric cancer. SBT6050 is a novel, systemically delivered antibody-drug conjugate that specifically targets **HER2** on tumor cells, delivering a potent **TLR8 agonist** directly to the tumor microenvironment to selectively activate myeloid cells and stimulate both innate and adaptive anti-tumor immune responses. Cemiplimab (brand name Libtayo) is a **fully human monoclonal antibody targeting PD-1**, functioning as an immune checkpoint inhibitor to enhance T-cell-mediated anti-tumor activity. The rationale for their combination is that SBT6050 can reprogram the tumor immune microenvironment to augment the efficacy of PD-1 blockade, potentially overcoming resistance to checkpoint inhibitors in HER2-expressing cancers[1][7].

Other names

SBT6050 and cemiplimabSBT-6050 and cemiplimabSBT 6050 and cemiplimabSBT6050 + Libtayo